-
Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives Med. Oncol. (IF 3.4) Pub Date : 2024-04-23 Alborz Soroush, Siavash Pourhossein, Dorrin Hosseingholizadeh, Ahmed Hjazi, Reza Shahhosseini, Haniyeh Kavoosi, Nazgol Kermanshahi, Parisa Behnamrad, Nima Ghavamikia, Mehdi Dadashpour, Sepideh Karkon Shayan
-
Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors Med. Oncol. (IF 3.4) Pub Date : 2024-04-23 Guangxun Yuan, Mengke Ye, Yixi Zhang, Xun Zeng
-
Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy Med. Oncol. (IF 3.4) Pub Date : 2024-04-23 Abdur Rauf, Payal B. Joshi, Ahmed Olatunde, Nabia Hafeez, Zubair Ahmad, Hassan A. Hemeg, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Muthu Thiruvengadam, Dhivya Viswanathan, Govindasamy Rajakumar, Rekha Thiruvengadam
-
Ferroptosis is an effective strategy for cancer therapy Med. Oncol. (IF 3.4) Pub Date : 2024-04-23 Afrasyab Khan, Yu Huo, Yilei Guo, Juanjuan Shi, Yongzhong Hou
-
N-methyl-D-aspartate receptors and thymoquinone induce apoptosis and alteration in mitochondria in colorectal cancer cells Med. Oncol. (IF 3.4) Pub Date : 2024-04-23 Ferhat Sirinyildiz, Simge Unay
-
FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner Med. Oncol. (IF 3.4) Pub Date : 2024-04-20 Zhe Yin, Xiong Guo, Xiaolong Liang, Ziwei Wang
-
Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach Med. Oncol. (IF 3.4) Pub Date : 2024-04-17 Ahad Amer Alsaiari, Amal F. Gharib, Maha Mahfouz Bakhuraysah, Amani A. Alrehaili, Shatha M. Algethami, Hayfa Ali Alsaif, Norah Al Harthi, Mohammed Ageeli Hakami
-
The role of SWI/SNF complexes in digestive system neoplasms Med. Oncol. (IF 3.4) Pub Date : 2024-04-17 Hanyun Liang, Xin Zheng, Xiao Zhang, Yan Zhang, Jie Zheng
-
Identification of small molecule inhibitors against Lin28/let-7 to suppress tumor progression and its alleviation role in LIN28-dependent glucose metabolism Med. Oncol. (IF 3.4) Pub Date : 2024-04-17 Rachanaa Raja, Rajamanikandan Sundararaj, Ruckmani Kandasamy
-
Liver cancer wars: plant-derived polyphenols strike back Med. Oncol. (IF 3.4) Pub Date : 2024-04-16 Chengu Niu, Jing Zhang, Patrick I. Okolo
-
Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma Med. Oncol. (IF 3.4) Pub Date : 2024-04-15 Sohini Roy, Geetha Shanmugam, Sudeshna Rakshit, R. Pradeep, Melvin George, Koustav Sarkar
-
Dual function of activated PPARγ by ligands on tumor growth and immunotherapy Med. Oncol. (IF 3.4) Pub Date : 2024-04-15 Mingjun Chen, Huijie Wang, Qian Cui, Juanjuan Shi, Yongzhong Hou
-
A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor Med. Oncol. (IF 3.4) Pub Date : 2024-04-11 Weijia Zhao, Min Mo, Jia Yu, Sha Cheng, Guiping Long, Zhiqiong Luo, Wei Liang, Chen Yan, Heng Luo, Baofei Sun
-
Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects Med. Oncol. (IF 3.4) Pub Date : 2024-04-09 Mohammad Ali Mirzadeh, Majid Eslami, Ali Ghanbari, Sam Zarbakhsh, Sedighe Yosefi, Abbas Pakdel
-
Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights Med. Oncol. (IF 3.4) Pub Date : 2024-04-09 Ahmadreza Lagzian, Marziye Askari, Melika Sadat Haeri, Nastaran Sheikhi, Sara Banihashemi, Mohsen Nabi-Afjadi, Yalda Malekzadegan
-
Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies Med. Oncol. (IF 3.4) Pub Date : 2024-04-09 Khubaib Ali, Muhammad Nabeel, Fatima Mohsin, Mehwish Iqtedar, Muhammad Islam, Muhammad Fawad Rasool, Furqan K. Hashmi, Syed Ahmed Hussain, Hamid Saeed
-
Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer Med. Oncol. (IF 3.4) Pub Date : 2024-04-09 Shahnaz Hosseinzadeh, Mahsa Imani, Farhad Pourfarzi, Narjes Jafari, Saeid AbedianKenari, Elham Safarzadeh
-
Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line Med. Oncol. (IF 3.4) Pub Date : 2024-04-09 Nazli Demirkiran, Bengusu Aydin, Melek Pehlivan, Zeynep Yuce, H. Ogun Sercan
-
Immunomodulatory effects of Diospyros peregrina fruit preparation (DFP) in non-small cell lung cancer (NSCLC) by utilizing dendritic cell-mediated antigen presentation and T helper (TH) cell differentiation Med. Oncol. (IF 3.4) Pub Date : 2024-04-05 Nawaneetan Sriraman, Ankita Sarkar, Sohom Naskar, Nitika Mahajan, Oishi Mukherjee, R. Pradeep, Melvin George, Koustav Sarkar
-
Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment Med. Oncol. (IF 3.4) Pub Date : 2024-04-04 Alaa Elmetwalli, Mohamed O. Abdel-Monem, Ali H. El-Far, Gehad S. Ghaith, Noaf Abdullah N. Albalawi, Jihan Hassan, Nadia F. Ismail, Tarek El-Sewedy, Mashael Mashal Alnamshan, Nouf K. ALaqeel, Ibtesam S. Al-Dhuayan, Mervat G. Hassan
-
Citalopram, an antipsychotic agent, induces G1/G0 phase cell cycle arrest and promotes apoptosis in human laryngeal carcinoma HEP-2 cells Med. Oncol. (IF 3.4) Pub Date : 2024-04-04 Mohammed Salama, Abeer Ali, Fawziya A. R. Ibrahim, Seham Elabd
-
Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy Med. Oncol. (IF 3.4) Pub Date : 2024-04-04 Jiejian Chen, Yonghao Li, Xiaoning Gan, Chengyin Weng, Xisheng Fang, Guolong Liu
It has been proposed that boron neutron capture therapy (BNCT) holds promise as a treatment modality for melanoma. However, the effectiveness of boron agents in delivery remains a critical issue to be addressed for BNCT. To this end, phenylboronic acid, which exhibits good water solubility and low cytotoxicity similar to BPA, has been investigated as a potential nuclear-targeting boron agent. The boron
-
Regulation of hippo signaling mediated apoptosis by Rauvolfia tetraphylla in triple-negative breast cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-29 B. Balavaishnavi, M. Kamaraj, T. G. Nithya, P. Santhosh, S. GokilaLakshmi, Mohammed Rafi Shaik
Rauvolfia tetraphylla is an essential medicinal plant that has been widely used in traditional medicine for various disease treatments. However, the tumor suppressor activity of R. tetraphylla and its phytocompounds were not explored against triple-negative breast cancer. The current research investigated the impact of R. tetraphylla methanolic extract (RTE) and its isolated compounds Ajmaline (RTC1)
-
Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-28 Abdulkarim S. Binshaya, Omar Saad Alkahtani, Fahad M. Aldakheel, Ahmed Hjazi, Hassan H. Almasoudi
-
Investigating the correlation between prominent viruses and hematological malignancies: a literature review Med. Oncol. (IF 3.4) Pub Date : 2024-03-28 Arian Haghtalab, Milad Hejazi, Naeem Goharnia, Ali Yekanlou, Kousha Hazhir, Asma Barghi, Zahra Bazzaz, Iman Allahverdizadeh, Ataollah GhalibafSabbaghi
Extensive research has been conducted on the correlation between viral infections and hematological cancers ever since the identification of the Rous Sarcoma Virus as a cancer-causing agent. Numerous viruses, such as the Epstein-Barr virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus 1, and severe acute respiratory syndrome-related coronavirus 2, have
-
Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review Med. Oncol. (IF 3.4) Pub Date : 2024-03-27 Sandipan Dasgupta, Sakuntala Gayen, Tania Chakraborty, Naureen Afrose, Ranita Pal, Sutapa Mahata, Vilas Nasare, Souvik Roy
-
YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis Med. Oncol. (IF 3.4) Pub Date : 2024-03-27 Yuanben Wang, Yulin Cao, Ying Chen, Han Cheng, Zhiang Liu, Mengna Wang, Yuyang Feng, Bojian Fei, Kaisa Cui, Zhaohui Huang
-
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-27 Anne-Dorthe Mosgaard Knudsen, Mikala Wej Modvig, Marianne Vogsen, Annette Raskov Kodahl
-
Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach Med. Oncol. (IF 3.4) Pub Date : 2024-03-26
Abstract Glioblastoma, a highly aggressive and lethal brain cancer, lacks effective treatment options and has a poor prognosis. In our study, we explored the potential anti-cancer effects of sodium butyrate (SB) and celastrol (CEL) in two glioblastoma cell lines. SB, a histone deacetylase inhibitor, and CEL, derived from the tripterygium wilfordii plant, act as mTOR and proteasome inhibitors. Both
-
Estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines Med. Oncol. (IF 3.4) Pub Date : 2024-03-25
Abstract Psychosocial stress promotes cancer pathogenesis involving angiogenesis through alterations in neuroendocrine-immune functions that may involve adrenoceptor (AR)-dependent signaling mechanisms in the brain, lymphoid organs, and cancerous cells. Various concentrations of α1- and α2- AR-specific agonists and antagonists were incubated in vitro with estrogen receptor-positive (ER +) MCF-7, and
-
Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing Med. Oncol. (IF 3.4) Pub Date : 2024-03-25 Kai Xiong, Yuqi Fang, Boyuan Qiu, Chaotao Chen, Nanchang Huang, Feiyuan Liang, Chuangming Huang, Tiantian Lu, Li Zheng, Jinmin Zhao, Bo Zhu
-
The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma Med. Oncol. (IF 3.4) Pub Date : 2024-03-25 Qing-Qing Liu, Xiang-Xu Wang, Hongchen Ji, Qiong-Yi Dou, Hong-Mei Zhang
-
Regulation of cancer progression by CK2: an emerging therapeutic target Med. Oncol. (IF 3.4) Pub Date : 2024-03-25 Shakeel Hussain, Yilei Guo, Yu Huo, Juanjuan Shi, Yongzhong Hou
-
Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation Med. Oncol. (IF 3.4) Pub Date : 2024-03-25
Abstract 5-Fluorouracil (5-FU) is an anticancer agent belonging to BCS Class III that exhibits poor release characteristics and low retention in the biological system. The main objective of this investigation was to develop a drug delivery system, i.e., Nanostructure Lipid Carriers (NLCs) loaded with 5-FU to prolong its biological retention through 5-FU-loaded NLCs (5-FUNLC) were designed to manipulate
-
Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment Med. Oncol. (IF 3.4) Pub Date : 2024-03-25 XiangFei Zhao, RuGang Zhao, JuYi Wen, Xia Zhang, ShanShan Wu, Juan Fang, JunPeng Ma, LiPin Gao, Yi Hu
-
Design and evaluation of a multiepitope vaccine for pancreatic cancer using immune-dominant epitopes derived from the signature proteome in expression datasets Med. Oncol. (IF 3.4) Pub Date : 2024-03-24 Sooram Banesh, Nupoor Patil, Vihadhar Reddy Chethireddy, Arnav Bhukmaria, Prakash Saudagar
-
Plumbagin as a preferential lead molecule to combat EGFR-driven matrix abundance and migration of cervical carcinoma cells Med. Oncol. (IF 3.4) Pub Date : 2024-03-23 Sneha Krishnamoorthy, Rajalakshmi Sabanayagam, Loganayaki Periyasamy, Bharathi Muruganantham, Sridhar Muthusami
-
In vitro anticancer activity of Hirudinaria manillensis methanolic extract and its validation using in silico molecular docking approach Med. Oncol. (IF 3.4) Pub Date : 2024-03-15 P. Zeebul Trinita Shannan, Susan G. Suganya, E. Angel Jemima, M. Ramesh
-
Role of interferon-induced transmembrane protein family in cancer progression: a special focus on pancreatic cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-12 Peipei Wang, Yan Pan, Yu Zhang, Congliang Chen, Junmei Hu, Xia Wang
-
High expression of CD9 and Epidermal Growth Factor Receptor promotes the development of tongue cancer Med. Oncol. (IF 3.4) Pub Date : 2024-03-12
Abstract Tongue cancer is distinguished by aggressive behavior, a high risk of recurrence, lymph, and distant metastases. Hypoxia-Induced Factor 1 α functions as a CD9 transcription factor. CD9 is a transmembrane protein that may be found on the cell membrane. It can modulate the expression of the Epidermal Growth Factor Receptor (EGFR) pathway. ELISA was used to measure serum CD9, p-EGFR, and p-Akt
-
The cytotoxic effects of prazosin, chlorpromazine, and haloperidol on hepatocellular carcinoma and immortalized non-tumor liver cells Med. Oncol. (IF 3.4) Pub Date : 2024-03-12
Abstract Liver cancer annually accounts for over 800,000 cases and 700,000 deaths worldwide. Hepatocellular carcinoma is responsible for over 80% of liver cancer cases. Due to ineffective treatment options and limited surgical interventions, hepatocellular carcinoma is notoriously difficult to treat. Nonetheless, drugs utilized for other medical conditions, such as the antihypertensive medication prazosin
-
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator Med. Oncol. (IF 3.4) Pub Date : 2024-03-05 Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
-
Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2024-03-04 Aydemir ASDEMİR, Aykut ÖZGÜR
-
An effective treatment approach of liposomally encapsulated metformin in colon cancer Med. Oncol. (IF 3.4) Pub Date : 2024-02-28
Abstract Metformin is a drug that is widely used in the treatment of type-2 diabetes and its anticarcinogenic effect has been detected in many studies since the 2000s. Metformin has a short half-life and poor biocompatibility, which limits the activity of the drug. As a solution to this situation, our study aimed to increase the anticarcinogenic effects and reduce the side effects of metformin in colon
-
Exploring the Potential of Essential Oil from Plectranthus amboinicus Leaves against Breast Cancer: In vitro and In silico Analysis Med. Oncol. (IF 3.4) Pub Date : 2024-02-24 Khushi Gupta, Pranay Gautre, Avadh Biharee, Yogesh Singh, Umesh Kumar Patil, Shashank Kumar, Suresh Thareja
-
Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Ian M. Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Thuy Ho, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant, Keri R. Maher
-
TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Yu-Ting Yin, Lu Shi, Chun Wu, Mei-Yin Zhang, Jia-Xin Li, Yu-Feng Zhou, Shuo-Cheng Wang, Hui-Yun Wang, Shi-Juan Mai
-
Estrogen-related receptor alpha (ERRα) promotes the migration, invasion and angiogenesis of breast cancer stem cell-like cells Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Kartik Muduli, Jagannath Pradhan, Monica Prusty, Archana Priyadarshini Samal, K Sony Reddy, Selvakumar Elangovan
-
Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS) Med. Oncol. (IF 3.4) Pub Date : 2024-02-23 Alexander S. Taylor, Rahul Mannan, Liron Pantanowitz, Arul M. Chinnaiyan, Saravana M. Dhanasekaran, Steven Hrycaj, Xuhong Cao, May P. Chan, David Lucas, Xiao-Ming Wang, Rohit Mehra
-
Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity Med. Oncol. (IF 3.4) Pub Date : 2024-02-21 Qiang You, Rong Li, Jia Yao, Ying-Cai Zhang, Xin Sui, Cui-Cui Xiao, Jie-Bin Zhang, Jia-Qi Xiao, Hai-Tian Chen, Hua Li, Jian Zhang, Jun Zheng, Yang Yang
-
Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target Med. Oncol. (IF 3.4) Pub Date : 2024-02-20
Abstract Urothelial Carcinoma of Bladder is complex disease with high mortality and recurrence rates. Current standard regimes have exhibited anti-tumor activity but still, a proportion of patients are non-responsive or in-eligible to receive such treatments. Immune checkpoints have emerged as potential class of therapeutics to be tested in UCB patients. Clinical trials targeting PD-1/PD-L1 axis have
-
Advancements in biosensors for cancer detection: revolutionizing diagnostics Med. Oncol. (IF 3.4) Pub Date : 2024-02-19 Syed Khalid Mustafa, Mohd. Farhan Khan, Mehak Sagheer, Deepak Kumar, Sadanand Pandey
-
CRP inhibits the osteoblastic differentiation of OPCs via the up-regulation of primary cilia and repression of the Hedgehog signaling pathway Med. Oncol. (IF 3.4) Pub Date : 2024-02-12 Jie Xu, Xiangmei Wu, Huifang Zhu, Yinghua Zhu, Kailong Du, Xiaoyan Deng, Changdong Wang
-
Selective targeting or reprogramming of intra-tumoral Tregs Med. Oncol. (IF 3.4) Pub Date : 2024-02-11 Keywan Mortezaee
-
The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study Med. Oncol. (IF 3.4) Pub Date : 2024-02-10 Abbas Alalikhan, Safieh Ebrahimi, Ali Aliee, Farshad Mirzavi, Seyed Isaac Hashemy
-
A therapeutical insight into the correlation between circRNAs and signaling pathways involved in cancer pathogenesis Med. Oncol. (IF 3.4) Pub Date : 2024-02-04 Raed Obaid Saleh, Sulieman Ibraheem Shelash Al-Hawary, Saade Abdalkareem Jasim, Dmitry Olegovich Bokov, Ahmed Hjazi, Khulood H. Oudaha, Mohammed Jawad Alnajar, Sally Salih Jumaa, Ahmed Alawadi, Ali Alsalamy
-
Regulation of the P53 tumor suppressor gene and the Mcl-2 oncogene expression by an active herbal component delivered through a smart thermo-pH-sensitive PLGA carrier to improve Osteosarcoma treatment Med. Oncol. (IF 3.4) Pub Date : 2024-01-30 Parinaz Akbari, Mohammad Taebpour, Milad Akhlaghi, Shaimaa Hamid Hasan, Shayesteh Shahriyari, Mahdieh Parsaeian, Bibi Fatemeh Haghirosadat, Abbas Rahdar, Sadanand Pandey
-
Unlocking the ‘ova’-coming power: immunotherapy’s role in shaping the future of ovarian cancer treatment Med. Oncol. (IF 3.4) Pub Date : 2024-01-29 Nathan A. Haines, Mia G. Fowler, Benjamin G. Zeh, Carter B. Kriete, Qian Bai, Mark R. Wakefield, Yujiang Fang
-
Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1 Med. Oncol. (IF 3.4) Pub Date : 2024-01-28 Jackie L. Ha, Erin Kaser, Tianyun Guan, Trenton G. Mayberry, Luke A. Smith, Kyle D’mello, Qian Bai, Mark R. Wakefield, Lijun Dong, Yujiang Fang
-
Pyroptosis in cancer treatment and prevention: the role of natural products and their bioactive compounds Med. Oncol. (IF 3.4) Pub Date : 2024-01-28
Abstract Targeting programmed cell death (PCD) has been emerging as a promising therapeutic strategy in cancer. Pyroptosis, as a type of PCDs, leads to the cleavage of the gasdermin family and the secretion of pro-inflammatory factors. Gasdermin D (GSDMD) and gasdermin E (GSDME) are the two main executors of pyroptosis. Pyroptosis in tumor and immune cells is essential for tumor progression. Natural